AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31942704 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of set size effects in feature search tasks
Number of subjects: 0
Study 31942704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis of individual differences in error patterns
Number of subjects: 0
Study 31020334 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily concurrent chemoradiation
Number of subjects: 75
Study 31020334 — intervention group
Group type: COMPARATOR
Intervention: Once-daily concurrent chemoradiation
Number of subjects: 75
Study 28431278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (50IU in solution)
Number of subjects: 43
Study 28431278 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (saline)
Number of subjects: 43
Study 25599708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic hypoglycemia (HH) - bolus insulin 0.1 IE/kg i.v.
Number of subjects: 9
Study 25599708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemia (HE) - bolus insulin 0.1 IE/kg i.v. and glucose 20% i.v. for 105 min
Number of subjects: 9
Study 25599708 — intervention group
Group type: COMPARATOR
Intervention: Saline control (CTR)
Number of subjects: 9
Study 23805994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (0.5 to 0.8 mEq/l)
Number of subjects: 0
Study 23805994 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 or 15 mg)
Number of subjects: 0
Study 21831726 — intervention group
Group type: EXPERIMENTAL
Intervention: Liprotamase (5 capsules per day, one capsule with each meal and snack)
Number of subjects: 138
Study 21831726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 capsule taken with meals and snacks)
Number of subjects: 138
Study 19360520 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple Communication Program
Number of subjects: 40
Study 19360520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 16721305 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson frame (Union City, CA)
Number of subjects: 0
Study 16721305 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens AG frame (Munich, Germany)
Number of subjects: 0
Study 16721305 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrews frame (Hollywood, CA)
Number of subjects: 0
Study 16721305 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson spine table (Hollywood, CA)
Number of subjects: 0
Study 16721305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolsters
Number of subjects: 0
Study 15583526 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 0
Study 15583526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes, antidepressants, alpha‐2 agonists, anticonvulsants, phytoestrogens, dietary supplements
Number of subjects: 0
Study 11744586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 FNB using 30 mL of ropivacaine 0.25%
Number of subjects: 48
Study 11744586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 FNB using 30 mL of ropivacaine 0.5%
Number of subjects: 48
Study 11744586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 FNB using 30 mL of bupivacaine 0.25%
Number of subjects: 48
Study 11744586 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 48
Study 9378180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in addition to usual EPI vaccines
Number of subjects: 124577
Study 9378180 — intervention group
Group type: COMPARATOR
Intervention: Usual EPI vaccines (BCG, DTP, OPV, measles, yellow fever)
Number of subjects: 124577
Study 8343610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat
Number of subjects: 0
Study 8343610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3311637 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinating center follow-up
Number of subjects: 0
Study 29554017 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence Dialogue Meeting (CDM) added to structured physiotherapy
Number of subjects: 352
Study 29554017 — intervention group
Group type: COMPARATOR
Intervention: Structured physiotherapy (Control)
Number of subjects: 352
Study 28256051 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS plus standard therapy
Number of subjects: 7
Study 28256051 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) therapy
Number of subjects: 7
Study 25940537 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 25940537 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 24007452 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth based remote medication adherence measurement system (mAMS)
Number of subjects: 53
Study 24007452 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no mAMS)
Number of subjects: 53
Study 21168822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine hydrochloride drops and a 4% lidocaine pledget
Number of subjects: 93
Study 21168822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine hydrochloride drops alone
Number of subjects: 93
Study 21168822 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cocaine (+ epinephrine 1/100,000) drops alone
Number of subjects: 93
Study 18315637 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 80
Study 18315637 — intervention group
Group type: COMPARATOR
Intervention: LMAU
Number of subjects: 80
Study 16487850 — intervention group
Group type: EXPERIMENTAL
Intervention: GUSTO bleeding (mild, moderate, severe)
Number of subjects: 15454
Study 16487850 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI bleeding (minimal, minor, major)
Number of subjects: 15454
Study 12620263 — intervention group
Group type: EXPERIMENTAL
Intervention: Left sided catheter insertion
Number of subjects: 75
Study 12620263 — intervention group
Group type: COMPARATOR
Intervention: Right sided catheter insertion
Number of subjects: 75
Study 11120525 — intervention group
Group type: COMPARATOR
Intervention: 125 mL intravenous fluids per hour
Number of subjects: 195
Study 11120525 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL intravenous fluids per hour
Number of subjects: 195
Study 9344298 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS) ambulation training (30 sessions)
Number of subjects: 32
Study 8250653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (25 mg of nicotine per 24 hours for 4 weeks, then 1 patch per day for 2 weeks)
Number of subjects: 159
Study 8250653 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 159
Study 3530613 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereophotogrammetry
Number of subjects: 0
Study 3530613 — intervention group
Group type: COMPARATOR
Intervention: Direct tracing and simple photography
Number of subjects: 0
Study 31112512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/mL (n=25)
Number of subjects: 50
Study 31112512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 9 mg/mL) (n=25)
Number of subjects: 50
Study 28268098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 1220
Study 26210489 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percentages of rTFA in plasma phospholipids (0.86 ± 0.24 %)
Number of subjects: 200
Study 26210489 — intervention group
Group type: COMPARATOR
Intervention: Concentrations of elaidic acid (a major iTFA) in plasma phospholipids
Number of subjects: 200
Study 23724529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS) - 4 ml spray solution (1 ml/puff X 4) applied topically
Number of subjects: 40
Study 23724529 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (0.9% NaCl) - 4 ml applied topically
Number of subjects: 40
Study 21855745 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based alcohol misuse prevention course (AlcoholEdu for College)
Number of subjects: 2700
Study 21855745 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 2700
Study 19548435 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus psychotherapy (Group B)
Number of subjects: 47
Study 19548435 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy alone (Group A)
Number of subjects: 47
Study 17259186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet and discussion group
Number of subjects: 92
Study 17259186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet group
Number of subjects: 92
Study 17259186 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 17259186 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion group
Number of subjects: 92
Study 15529389 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/day for 1 year
Number of subjects: 60
Study 15529389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11472323 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC with clarithromycin and metronidazole
Number of subjects: 118
Study 11472323 — intervention group
Group type: COMPARATOR
Intervention: RBC with clarithromycin
Number of subjects: 118
Study 9826048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute interval
Number of subjects: 270
Study 9826048 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minute interval
Number of subjects: 270
Study 9826048 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 minute interval
Number of subjects: 270
Study 9826048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minute interval
Number of subjects: 270
Study 9826048 — intervention group
Group type: COMPARATOR
Intervention: 2 minute interval
Number of subjects: 270
Study 9826048 — intervention group
Group type: COMPARATOR
Intervention: 10 minute interval
Number of subjects: 270
Study 10155090 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab (0.25 mg/kg bolus and 10 micrograms/min infusion for 12 hours)
Number of subjects: 2099
Study 10155090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study 2892729 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha (Prostin 15M), 0.25 mg every second hour
Number of subjects: 592
Study 2892729 — intervention group
Group type: EXPERIMENTAL
Intervention: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonylamide (Nalodor), 0.5 mg every fourth hour
Number of subjects: 592
Study 1064238 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment
Number of subjects: 0
Study 31229533 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 103
Study 31229533 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (coiling)
Number of subjects: 103
Study 28958437 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 40 mg/d
Number of subjects: 280
Study 28958437 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 160 mg/d
Number of subjects: 280
Study 28958437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 28958437 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 280
Study 25799080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 364
Study 25799080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 364
Study 22941790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 96
Study 22941790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 22941790 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 96
Study 22941790 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study 21367400 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Emotional Disclosure (WED)
Number of subjects: 0
Study 21367400 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 0
Study 19375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging with fast RNFL thickness protocol
Number of subjects: 77
Study 19375690 — intervention group
Group type: COMPARATOR
Intervention: Nonfellow pairs of eyes (control)
Number of subjects: 77
Study 17328944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) administered at graded doses (0.2, 0.6, and 2.0 microg/min)
Number of subjects: 39
Study 17328944 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (PA) administered at 12 mg
Number of subjects: 39
Study 14718288 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 30
Study 14718288 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 30
Study 11715357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril
Number of subjects: 3577
Study 11715357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study 9218236 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping counseling (n = 82)
Number of subjects: 155
Study 9218236 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (n = 73)
Number of subjects: 155
Study 8263086 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery/relaxation tape before and during MRI (n = 20)
Number of subjects: 41
Study 8263086 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 41
Study 3138131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (15 mg p.o.)
Number of subjects: 103
Study 3138131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 103
Study 3138131 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum urine flow
Number of subjects: 103
Study 30777713 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized CAD/CAM prostheses (group 2)
Number of subjects: 28
Study 30777713 — intervention group
Group type: COMPARATOR
Intervention: Stock prostheses (group 1)
Number of subjects: 28
Study 30777713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 28474588 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 240
Study 28474588 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 240
Study 26152693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue add-on (S3)
Number of subjects: 23
Study 26152693 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma drops (S2)
Number of subjects: 23
Study 26152693 — intervention group
Group type: COMPARATOR
Intervention: Untreated (S1)
Number of subjects: 23
Study 26152693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group of other glaucoma medications (S2)
Number of subjects: 23
Study 26152693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosinor amplitudes
Number of subjects: 23
Study 26152693 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under receiver operating curve (AUC)
Number of subjects: 23
Study 24092827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (1 mg/d)
Number of subjects: 36
Study 24092827 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg/d)
Number of subjects: 36
Study 24092827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24092827 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training with estradiol
Number of subjects: 36
Study 24092827 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise training with placebo
Number of subjects: 36
Study 24092827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 36
Study 21345418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behaviour Therapy (CBT‐E), average of 20‐40 individual sessions with a clinical psychologist
Number of subjects: 125
Study 21345418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behaviour Therapy (CBT‐E)
Number of subjects: 125
Study 18603204 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective neck dissection (SND) of levels I through III
Number of subjects: 0
Study 18603204 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective treatment of the neck lymphatics
Number of subjects: 0
Study 18603204 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 0
Study 18543684 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane treatment (Group A)
Number of subjects: 36
Study 18543684 — intervention group
Group type: COMPARATOR
Intervention: Purified water treatment (Group B)
Number of subjects: 36
Study 15605331 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program (12-week duration, including hip flexion range of motion exercises, strengthening exercises for bilateral hip flexors, extensors, and abductors, and a daily 30-minute walk)
Number of subjects: 53
Study 15605331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 53
Study 11726485 — intervention group
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy assessment of muscle oxygenation
Number of subjects: 26
Study 11726485 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy young men)
Number of subjects: 26
Study 9204352 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol (Imagopaque 300)
Number of subjects: 96
Study 9204352 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate (Urografin 292)
Number of subjects: 96
Study 9204352 — intervention group
Group type: COMPARATOR
Intervention: iohexol (Omnipaque 300)
Number of subjects: 96
Study 8260367 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMV3 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 3 courses)
Number of subjects: 458
Study 8260367 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMV6 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 6 courses)
Number of subjects: 458
Study 8260367 — intervention group
Group type: EXPERIMENTAL
Intervention: EI6 (Etoposide and Ifosfamide for 6 courses)
Number of subjects: 458
Study 3307228 — intervention group
Group type: EXPERIMENTAL
Intervention: Partusisten
Number of subjects: 0
Study 3307228 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study 30946851 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 360
Study 30946851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral agents including sulphonylurea
Number of subjects: 360
Study 30946851 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous episodes of hypoglycemia before Ramadan
Number of subjects: 360
Study 30946851 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fasting during Ramadan
Number of subjects: 360
Study 30946851 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c and weight post Ramadan fasting
Number of subjects: 360
Study 27626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Experimental (LI-E)
Number of subjects: 35
Study 27626795 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Control (HI-C)
Number of subjects: 35
Study 26299164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid (LAc) treatment in low P diet
Number of subjects: 2
Study 26299164 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (CAc) treatment in low P diet
Number of subjects: 2
Study 26299164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid (LAc) treatment
Number of subjects: 2
Study 26299164 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (CAc) treatment
Number of subjects: 2
Study 26299164 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (CAc) and Lactic acid (LAc) treatments
Number of subjects: 2
Study 26299164 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 2
Study 24464531 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 8
Study 24464531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 8
Study 24464531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Naltrexone (50 mg) and Alprazolam (0.5 mg)
Number of subjects: 8
Study 24464531 — intervention group
Group type: COMPARATOR
Intervention: Oral d-amphetamine (0, 15, and 30 mg)
Number of subjects: 8
Study 24464531 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (0 mg)
Number of subjects: 8
Study 24464531 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (0 mg)
Number of subjects: 8
Study 21948030 — intervention group
Group type: EXPERIMENTAL
Intervention: Short proximal femoral nail antirotation (PFNA)
Number of subjects: 81
Study 21948030 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 81
Study 19554672 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS) administered every 2 weeks for 6 months
Number of subjects: 160
Study 19554672 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis controlling for significant covariates
Number of subjects: 160
Study 17342639 — intervention group
Group type: EXPERIMENTAL
Intervention: Human bocavirus detected in children with acute wheezing
Number of subjects: 259
Study 17342639 — intervention group
Group type: EXPERIMENTAL
Intervention: High viral loads of human bocavirus
Number of subjects: 259
Study 17342639 — intervention group
Group type: EXPERIMENTAL
Intervention: Human bocavirus DNA in serum specimens
Number of subjects: 259
Study 17342639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low viral loads of human bocavirus
Number of subjects: 259
Study 14982884 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOEP (CHOP plus etoposide 100 mg/m2 days 1-3)
Number of subjects: 710
Study 14982884 — intervention group
Group type: COMPARATOR
Intervention: CHOP (standard chemotherapy)
Number of subjects: 710
Study 14982884 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval reduction (biweekly regimens)
Number of subjects: 710
Study 11195894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger expression (e.g., President Clinton expressing anger about the Monica Lewinsky scandal)
Number of subjects: 0
Study 11195894 — intervention group
Group type: COMPARATOR
Intervention: Sadness expression (e.g., President Clinton expressing sadness about the Monica Lewinsky scandal)
Number of subjects: 0